WO2003048202A3 - Nf-kappab activating genes - Google Patents

Nf-kappab activating genes Download PDF

Info

Publication number
WO2003048202A3
WO2003048202A3 PCT/JP2002/012644 JP0212644W WO03048202A3 WO 2003048202 A3 WO2003048202 A3 WO 2003048202A3 JP 0212644 W JP0212644 W JP 0212644W WO 03048202 A3 WO03048202 A3 WO 03048202A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
dna
activating
recombinant vector
activation
Prior art date
Application number
PCT/JP2002/012644
Other languages
French (fr)
Other versions
WO2003048202A2 (en
Inventor
Akio Matsuda
Shuji Muramatsu
Original Assignee
Asahi Kasei Pharma Corp
Akio Matsuda
Shuji Muramatsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001368692A external-priority patent/JP2006166701A/en
Priority claimed from JP2002291302A external-priority patent/JP2006166705A/en
Application filed by Asahi Kasei Pharma Corp, Akio Matsuda, Shuji Muramatsu filed Critical Asahi Kasei Pharma Corp
Priority to AU2002349784A priority Critical patent/AU2002349784A1/en
Publication of WO2003048202A2 publication Critical patent/WO2003048202A2/en
Publication of WO2003048202A3 publication Critical patent/WO2003048202A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Provided are proteins capable of activating NF-κB, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-κB. Using plasmid pNFκB-Luc, cDNA encoding a protein capable of activating NF-κB has been cloned from a cDNA library constructed from human lung fibroblasts and the like, and the DNA sequence and the deduced amino acid sequence determined. The protein, the DNA encoding the protein, a recombinant vector containing the DNA, and a transformant containing the recombinant vector are useful for screening a substance inhibiting or promoting NF-κB activation.
PCT/JP2002/012644 2001-12-03 2002-12-03 Nf-kappab activating genes WO2003048202A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002349784A AU2002349784A1 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2001-368692 2001-12-03
JP2001368692A JP2006166701A (en) 2001-12-03 2001-12-03 NF-kappaB ACTIVATING GENE
US33582901P 2001-12-05 2001-12-05
US60/335,829 2001-12-05
JP2002291302A JP2006166705A (en) 2002-10-03 2002-10-03 NF-kappaB ACTIVATING GENE
JP2002-291302 2002-10-03
US41576902P 2002-10-04 2002-10-04
US60/415,769 2002-10-04

Publications (2)

Publication Number Publication Date
WO2003048202A2 WO2003048202A2 (en) 2003-06-12
WO2003048202A3 true WO2003048202A3 (en) 2004-07-01

Family

ID=27482716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012644 WO2003048202A2 (en) 2001-12-03 2002-12-03 Nf-kappab activating genes

Country Status (2)

Country Link
AU (1) AU2002349784A1 (en)
WO (1) WO2003048202A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
WO2004003191A1 (en) * 2002-06-26 2004-01-08 Bayer Healthcare Ag Regulation of human map kinase kinase kinase
AU2003301621A1 (en) * 2002-10-22 2004-05-13 Oregon Health And Science University Apoptotic response regulation through interaction of tripartite motif protein 32 with pias
AU2003290432A1 (en) * 2002-12-26 2004-07-22 Asahi Kasei Pharma Corporation T cell activating gene
WO2004106937A2 (en) * 2003-06-02 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled p2y purinoreceptor 6 (p2y6)
WO2004111088A2 (en) * 2003-06-10 2004-12-23 Xantos Biomedicine Ag Angiogenic factor and inhibitors thereof
KR101192496B1 (en) 2003-11-06 2012-10-18 시애틀 지네틱스, 인크. Monomethylvaline compounds capable of conjugation to ligands
CN114053429A (en) 2004-06-01 2022-02-18 健泰科生物技术公司 Antibody-drug conjugates and methods
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2412947C2 (en) 2004-09-23 2011-02-27 Дженентек, Инк. Antibodies, constructed on cysteine basis and their conjugates
JP2007054042A (en) * 2005-07-26 2007-03-08 Japan Science & Technology Agency Interferon-inducing molecule ips-1
JP2011529708A (en) * 2008-08-04 2011-12-15 ユニバーシティ オブ マイアミ Innate immune response regulator STING (interferon gene stimulator)
US20110212111A1 (en) * 2008-11-04 2011-09-01 Cambier John C MHC II Associated Protein and Uses Thereof
JP2013504585A (en) 2009-09-09 2013-02-07 セントローズ， エルエルシー Extracellular targeted drug complex
PE20130342A1 (en) 2010-04-15 2013-04-20 Spirogen Sarl PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2816426A1 (en) 2010-11-17 2012-06-07 Genentech, Inc. Alaninyl maytansinol antibody conjugates
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CN103030688B (en) * 2011-09-30 2014-09-17 北京大学 Short chain polypeptide for inhibiting cancer cell growth as well as encoding gene and application of short chain polypeptide
KR101877598B1 (en) 2011-10-14 2018-07-11 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2906297B1 (en) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
JP6392763B2 (en) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ Pyrrolobenzodiazepine-antibody conjugate
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
ES2670937T3 (en) 2012-10-12 2018-06-04 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
ES2680153T3 (en) 2012-10-12 2018-09-04 Adc Therapeutics Sa Anti-PSMA-pyrrolobenzodiazepine antibody conjugates
RS56520B1 (en) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
BR112015023070B1 (en) 2013-03-13 2022-06-07 Genentech, Inc. Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition comprising the same, as well as their uses for the treatment of a proliferative disease
JP6340019B2 (en) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
BR112015023333A8 (en) 2013-03-13 2018-04-17 Medimmune Ltd pyrrolbenzodiazepines and conjugates thereof
WO2015023355A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
RU2689388C1 (en) 2013-12-16 2019-05-28 Дженентек, Инк. Peptidomimetic compounds and their conjugates of antibodies with drugs
JP6980384B2 (en) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド 1- (Chloromethyl) -2,3-dihydro-1H-benzo [E] indole dimer antibody-drug conjugate compound, and methods of use and treatment
AU2014364927A1 (en) 2013-12-16 2016-07-07 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
RU2017107502A (en) 2014-09-12 2018-10-12 Дженентек, Инк. ANTIBODIES AND CONJUGATES DESIGNED BY THE INTRODUCTION OF CYSTEINE
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170067771A (en) 2014-09-17 2017-06-16 제넨테크, 인크. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
EP3223854A1 (en) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
KR20170086121A (en) 2014-12-03 2017-07-25 제넨테크, 인크. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018144775A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
MX2019009428A (en) 2017-02-08 2019-10-07 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates.
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE059828T2 (en) 2017-04-18 2023-01-28 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP7408396B2 (en) 2017-04-20 2024-01-05 アーデーセー セラピューティクス ソシエテ アノニム combination therapy
BR112019026564A2 (en) 2017-06-14 2020-06-30 Adc Therapeutics Sa dosing regimens for administration of an anti-cd19 adc
LT3668874T (en) 2017-08-18 2022-03-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL302943A (en) 2017-09-20 2023-07-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (en) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023045A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim International Gmbh Method of inhibiting the transcription of genes
WO1996017927A2 (en) * 1994-12-05 1996-06-13 Karo Bio Ab Reporter cell line
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
EP0955372A2 (en) * 1998-03-20 1999-11-10 Suntory Limited Method for screening substance inhibiting activation of NF-kappa B
WO2001072296A1 (en) * 2000-03-27 2001-10-04 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023045A1 (en) * 1993-04-07 1994-10-13 Boehringer Ingelheim International Gmbh Method of inhibiting the transcription of genes
WO1996017927A2 (en) * 1994-12-05 1996-06-13 Karo Bio Ab Reporter cell line
US5932425A (en) * 1997-02-18 1999-08-03 Signal Pharmaceuticals, Inc. Compositions and methods for modulating cellular NF-κB activation
EP0955372A2 (en) * 1998-03-20 1999-11-10 Suntory Limited Method for screening substance inhibiting activation of NF-kappa B
WO2001072296A1 (en) * 2000-03-27 2001-10-04 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 April 1992 (1992-04-01), retrieved from EBI Database accession no. M86377 *
DATABASE EMBL [online] 27 February 1992 (1992-02-27), retrieved from EBI Database accession no. M86699 *
DATABASE EMBL [online] XP002233369, retrieved from EBI Database accession no. BC000633 *
DOUVILLE E M J ET AL: "MULTIPLE CDNAS ENCODING THE ESK KINASE PREDICT TRANSMEMBRANE AND INTRACELLULAR ENZYME ISOFORMS", MOLECULAR AND CELLULAR BIOLOGY, vol. 12, no. 6, 1992, pages 2681 - 2689, XP009006945, ISSN: 0270-7306 *
KWON BYUNGSUK ET AL: "Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand", JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC.,, US, vol. 274, no. 10, 5 March 1999 (1999-03-05), pages 6056 - 6061, XP002147323, ISSN: 0021-9258 *
MILLS G B ET AL: "EXPRESSION OF TTK A NOVEL HUMAN PROTEIN KINASE IS ASSOCIATED WITH CELL PROLIFERATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 22, M86699, 1992, pages 16000 - 16006, XP002233366, ISSN: 0021-9258, Retrieved from the Internet <URL:EBI> *
WANG CUN-YU ET AL: "NK-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.", SCIENCE (WASHINGTON D C), vol. 281, no. 5383, pages 1680 - 1683, XP002233368, ISSN: 0036-8075 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases

Also Published As

Publication number Publication date
AU2002349784A8 (en) 2003-06-17
WO2003048202A2 (en) 2003-06-12
AU2002349784A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
WO2003048202A3 (en) Nf-kappab activating genes
WO2004043382A3 (en) Enhanced variants of erythropoietin and methods of use
GB2292382B (en) Obesity (OB) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vect
EP1308459A3 (en) Full-length cDNA sequences
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
WO2002061076A1 (en) Adiponectin-associated protein
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO2003042362A3 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2002077171A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2003031598A3 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
WO1997022695A3 (en) Nucleotide sequences, proteins, drugs and diagnostic agents for treating cancer
WO2000061742A3 (en) Treatment of cardiac power failure using s100 proteins
WO2004069200A3 (en) Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases
EP1281763A3 (en) Early growth response-1 (EGR-1) transcription factor
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
WO1998011234A3 (en) Human protein kinases
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
WO2000040723A3 (en) Methods and products for delivering nucleic acids
WO2003104277A3 (en) Stat6 activation gene
WO2002040683A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2003048303A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2004078112A3 (en) Apoptosis inducing gene
WO2002018536A3 (en) Truncated bard1 protein, and its diagnostic and therapeutic uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase